Ferring Leapfrogs Into Late-Stage Microbiome Race With Rebiotix Buy
The Swiss specialty drug company gains a Phase III microbiome product for the prevention of recurrent Clostridium difficile infection and a broader platform for Microbiota Restoration Therapy.
You may also be interested in...
If all goes well, 2020 could see the Swiss firm's Rebiotix subsidiary get a green light from the FDA for its recurrent Clostridioides difficile fecal product.
The firms have inked a collaboration which aims to explore individual differences in women’s responses to IVF treatment, improve success rates and reduce side effects such as ovarian hyper-stimulation syndrome.
Genentech is to work with microbiome therapeutics company Microbiotica in a collaboration to discover, develop and commercialise treatments for inflammatory bowel disease.